Literature DB >> 9271038

Prospective study of fluconazole therapy in systemic neonatal fungal infection.

S Wainer1, P A Cooper, H Gouws, A Akierman.   

Abstract

BACKGROUND: Standard neonatal systemic antifungal therapy with amphotericin B and flucytosine can be associated with toxicity, drug resistance and the need for prolonged venous access. There is consequently a need for alternative treatment options.
OBJECTIVES: To assess the efficacy and safety of fluconazole in the treatment of systemic neonatal fungal infections.
METHOD: Open, nonrandomized evaluation of fluconazole treatment in 20 consecutively enrolled neonates with systemic fungal infection.
RESULTS: Clinical and microbiologic cure was achieved in 12 of 19 (63%) of infants treated. One additional infant received prior amphotericin B therapy and is included for assessment of side effects. One infant with Torulopsis glabrata infection failed treatment. Six infants died of Gram-negative bacterial infection and other intercurrent medical problems.
CONCLUSION: Fluconazole appeared to be safe and effective for treatment of systemic candidal infection in the neonate although more data are required in very low birth weight infants.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9271038     DOI: 10.1097/00006454-199708000-00007

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  8 in total

1.  Candida isolates from neonates: frequency of misidentification and reduced fluconazole susceptibility.

Authors:  J L Rowen; J M Tate; N Nordoff; L Passarell; M R McGinnis
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

2.  Antifungal therapy and outcomes in infants with invasive Candida infections.

Authors:  Simon B Ascher; P Brian Smith; Kevin Watt; Daniel K Benjamin; Michael Cohen-Wolkowiez; Reese H Clark; Daniel K Benjamin; Cassandra Moran
Journal:  Pediatr Infect Dis J       Date:  2012-05       Impact factor: 2.129

Review 3.  Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants.

Authors:  David Kaufman; Karen D Fairchild
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

Review 4.  Antifungals in systemic neonatal candidiasis.

Authors:  Daniel A C Frattarelli; Michael D Reed; George P Giacoia; Jacob V Aranda
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Management of neonatal candidiasis. Neonatal Candidiasis Study Group.

Authors:  J L Rowen; J M Tate
Journal:  Pediatr Infect Dis J       Date:  1998-11       Impact factor: 2.129

6.  Community-acquired and hospital-acquired candiduria: comparison of prevalence and clinical characteristics.

Authors:  R Colodner; Y Nuri; B Chazan; R Raz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-12-21       Impact factor: 3.267

Review 7.  Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.

Authors:  Jessica K Roberts; Chris Stockmann; Jonathan E Constance; Justin Stiers; Michael G Spigarelli; Robert M Ward; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

Review 8.  Safety of fluconazole in paediatrics: a systematic review.

Authors:  Oluwaseun Egunsola; Abiodun Adefurin; Apostolos Fakis; Evelyne Jacqz-Aigrain; Imti Choonara; Helen Sammons
Journal:  Eur J Clin Pharmacol       Date:  2013-01-17       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.